fidaxomicin has been researched along with Critical-Illness* in 2 studies
2 other study(ies) available for fidaxomicin and Critical-Illness
| Article | Year |
|---|---|
Successful treatment of severe Clostridium difficile infection by administration of crushed fidaxomicin via a nasogastric tube in a critically ill patient.
To report the successful use of crushed fidaxomicin via a nasogastric tube for treatment of a severe Clostridium difficile infection in a critically ill patient.. Clinical observation of a patient, images of abdominal computed tomography, antimicrobial therapy and course of infection parameters.. Relevant information contained in the medical observation of the patient and selection of image and laboratory parameters performed in the patient.. We report a case of a 79-year old patient who developed septic shock with an increasing need for norepinephrine and acute renal failure due to a severe Clostridium difficile infection. Antimicrobial therapy with vancomycin via a nasogastric tube and metronidazole i.v. did not lead to improvement, infection parameters further increased, and the clinical condition became increasingly impaired. After 10 days, antimicrobial therapy was changed to fidaxomicin, crushed and administered via nasogastric tube. Within 24hours, infection parameters decreased. Further diarrhoea ceased and stool samples were negative for Clostridium difficile antigen.. Our case confirms that administration of fidaxomicin via a nasogastric tube was safe and effective in this patient. Further studies are needed to evaluate the efficacy of this strategy in critically ill patients systematically. Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Critical Illness; Diarrhea; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Intubation, Gastrointestinal; Shock, Septic; Treatment Outcome | 2017 |
Fidaxomicin therapy in critically ill patients with Clostridium difficile infection.
Fidaxomicin use to treat proven Clostridium difficile infection (CDI) was compared between 20 patients receiving care in critical care units (CCUs) and 30 patients treated on general medical floors. At baseline, the CCU patients had more initial CDI episodes, more severe and complicated disease, and more concurrent broad-spectrum antibiotic coverage. On multivariate analysis, the response to fidaxomicin therapy among the critically ill patients was comparable to that among patients in the general medical wards. Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Critical Illness; Female; Fidaxomicin; Humans; Male; Middle Aged; Patients' Rooms | 2015 |